148.03
+0.22(+0.15%)
Currency In USD
| Previous Close | 147.81 |
| Open | 147.63 |
| Day High | 149.59 |
| Day Low | 147.56 |
| 52-Week High | 152.94 |
| 52-Week Low | 75.56 |
| Volume | 207,652 |
| Average Volume | 531,473 |
| Market Cap | 7.46B |
| PE | -31.7 |
| EPS | -4.67 |
| Moving Average 50 Days | 133.04 |
| Moving Average 200 Days | 117.25 |
| Change | 0.22 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) 10 years ago, it would be worth $17,212.79 as of December 04, 2025 at a share price of $148.03. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $1,848.99 as of December 04, 2025 at a share price of $148.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy NEW YORK, No
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
GlobeNewswire Inc.
Oct 09, 2025 11:00 AM GMT
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is recognizing Mental Illness Awarene
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
GlobeNewswire Inc.
Oct 07, 2025 11:00 AM GMT
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for